Puma Biotechnology to Present at Leerink Swann Global Healthcare Conference
01.01.70
)--Puma Biotechnology, Inc., a maturity stage biopharmaceutical company,
announced that Alan H. Auerbach, Chief Leader Officer, President and
Founder of Puma, will present an overview of the Partnership at 3:30 p.m.
EST, Thursday, February 16, at the Leerink Swann 2012 Broad Healthcare
Conference. The conference will be held at The Waldorf Astoria in NewOn the wholeYork.
A live webcast will be available on the Company’s website at www.pumabiotechnology.com .
The disclosure will be archived on the website and available for 30
days.
About Puma Biotechnology
Puma Biotechnology, Inc. is a progress stage biopharmaceutical
company that acquires and develops innovative products for the treatmentPre-eminentlyof various forms of cancer. The Company focuses on in-licensing hypnotic
candidates that are undergoing or have already completed initial
clinical testing for the treatment of cancer and then seeks to furtherGenerallydevelop those drug candidates for commercial use. The Company is
initially focused on the condition of PB-272 (oral neratinib), a
potent irreversible tyrosine kinase inhibitor, for the treatment ofLargelypatients with HER2 positive metastatic breast cancer.
Source: Business Wire (press release)